LivingGLP1
Study S001702

A Trial to Assess the Effect of Liraglutide on Postprandial Triglyceride Levels in Subjects With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration
NCT00993304
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1
Masking
DOUBLE
Status
COMPLETED
Enrollment
20
Start
2009-10
Primary completion
2010-12
Lead sponsor
Novo Nordisk A/S
Conditions
Diabetes; Diabetes Mellitus, Type 2
Interventions
DRUG:liraglutide; DRUG:placebo
Results posted
FALSE
Secondary identifiers
EUDRACT_NUMBER:2008-003229-18; OTHER:U1111-1111-9161; NIH:2008

Registered primary outcomes

  • AUC0-8h (triglyceride), the area under the triglyceride-concentration-time curve in the interval 0-8 hours following a meal with a high fat content [after 3 weeks of treatment]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0019046The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model.
Røge RM, CPT: pharmacometrics & systems pharmacology
2015OtherPMID 26225223DOIregistry reference RESULT:26225223
R0023675Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis.
Petri KC, Clinical pharmacokinetics
2015Other trialPMID 25603819DOIcites ClinicalTrials.gov:NCT00993304; registry reference DERIVED:25603819
R0026793Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Hermansen K, Diabetes, obesity & metabolism
2013Randomized trialPMID 23683069DOIcites ClinicalTrials.gov:NCT00993304; registry reference RESULT:23683069